Protara Therapeutics, Inc.
TARA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $128 | $173 | $140 |
| - Cash | $13 | $31 | $91 | $163 |
| + Debt | $2 | $4 | $4 | $4 |
| Enterprise Value | – | $101 | $86 | -$19 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$12 | -$16 | -$14 | -$14 |
| % Margin | – | – | – | – |
| Net Income | -$13 | -$15 | -$12 | -$13 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.31 | -0.35 | -0.29 | -0.48 |
| % Growth | 11.4% | -20.7% | 39.6% | – |
| Operating Cash Flow | -$12 | -$12 | -$15 | -$9 |
| Capital Expenditures | -$0 | -$0 | -$0 | $0 |
| Free Cash Flow | -$12 | -$12 | -$15 | -$9 |